María Elena Marsón1, Diego Dante Dana, Jaime Altcheh, Facundo García-Bournissen, Guido Mastrantonio. 1. Área de Toxicología, Departamento de Ciencias Biológicas, Facultad de Ciencias Exactas, Universidad Nacional de La Plata. La Plata, Provincia de Buenos Aires, Argentina; Laboratorio de Servicios a la Industria y al Sistema Científico (LaSeISiC), Universidad Nacional de La Plata / Comisión de Investigaciones Científicas de la Provincia de Buenos Aires, Argentina.
Abstract
OBJECTIVE: Chagas disease constitutes a major public health problem in Latin America. Correctly designed pharmacokinetic, safety, and bioequivalence studies are desirable in order to fill the knowledge gaps that presently exist on available drugs. It is necessary to develop accurate, simple, reproducible, and sensitive high-performance liquid chromatography (HPLC)/UV methods for the quantization of benznidazole (BNZ) in human plasma and urine for clinical applications, specially in pediatric patients. METHODS: Quantization of BNZ in human plasma involved freeze-drying and re-suspension in organic solvent followed by reverse phase HPLC with UV detection. Analysis of BNZ in urine involved liquid/liquid extraction followed by reverse phase HPLC with UV detection. RESULTS: Limits of quantization (LOQ) were 0.32 μg/ml for plasma and 5.2 μg/ml for urine. No metabolite interferences were showed in both methods. CONCLUSION: The LOQ of methods seems appropriate in pediatric clinical contexts. Both procedures were applied with good results, to the quantization of BNZ in plasma and urine of patients treated for Chagas disease.
OBJECTIVE:Chagas disease constitutes a major public health problem in Latin America. Correctly designed pharmacokinetic, safety, and bioequivalence studies are desirable in order to fill the knowledge gaps that presently exist on available drugs. It is necessary to develop accurate, simple, reproducible, and sensitive high-performance liquid chromatography (HPLC)/UV methods for the quantization of benznidazole (BNZ) in human plasma and urine for clinical applications, specially in pediatric patients. METHODS: Quantization of BNZ in human plasma involved freeze-drying and re-suspension in organic solvent followed by reverse phase HPLC with UV detection. Analysis of BNZ in urine involved liquid/liquid extraction followed by reverse phase HPLC with UV detection. RESULTS: Limits of quantization (LOQ) were 0.32 μg/ml for plasma and 5.2 μg/ml for urine. No metabolite interferences were showed in both methods. CONCLUSION: The LOQ of methods seems appropriate in pediatric clinical contexts. Both procedures were applied with good results, to the quantization of BNZ in plasma and urine of patients treated for Chagas disease.
Authors: Carmen R de Castro; María Montalto de Mecca; Silvia L Fanelli; Elida C de Ferreyra; Edith G Díaz; José A Castro Journal: Toxicology Date: 2003-09-30 Impact factor: 4.221
Authors: Marisa L Fernández; María E Marson; Guido E Mastrantonio; Marcelo A Corti; Ulises Fleitas; Susana C Lloveras; Nicolas Lista; Maria M Priarone; Cecilia Domínguez; Facundo Garcia-Bournissen Journal: Antimicrob Agents Chemother Date: 2021-02-17 Impact factor: 5.191
Authors: Luísa Perin; Rodrigo Moreira da Silva; Kátia da Silva Fonseca; Jamille Mirelle de Oliveira Cardoso; Fernando Augusto Siqueira Mathias; Levi Eduardo Soares Reis; Israel Molina; Rodrigo Correa-Oliveira; Paula Melo de Abreu Vieira; Cláudia Martins Carneiro Journal: Antimicrob Agents Chemother Date: 2017-03-24 Impact factor: 5.191
Authors: Marisa Liliana Fernández; Maria Elena Marson; Juan Carlos Ramirez; Guido Mastrantonio; Alejandro Gabriel Schijman; Jaime Altcheh; Adelina Rosa Riarte; Facundo García Bournissen Journal: Mem Inst Oswaldo Cruz Date: 2016-03-15 Impact factor: 2.743